Active — Not RecruitingPhase 1/2

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

United States, South Korea, Taiwan179 participantsStarted 2021-06-09

Plain-language summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit. * Adequate bone marrow, kidney and liver function. * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Patients with Dose-limiting Toxicities

Timeframe: Baseline up to 28 Days

Incidence of Adverse Events

Timeframe: Baseline up to Approximately 24 Months

Number of Patients with Clinically Significant Laboratory Abnormalities

Timeframe: Baseline up to Approximately 24 Months

Number of Patients in Expansion Cohorts with Objective Responses

Timeframe: Baseline up to approximately 24 months

Duration of Response for Patients in Expansion Cohorts

Timeframe: Baseline up to approximately 24 months

Progression-free Survival for Patients in Expansion Cohorts

Timeframe: Baseline up to approximately 24 months

Overall Survival for Patients in Combination Dose Expansion Cohorts

Timeframe: Up to approximately 48 months

Trial details

NCT IDNCT04913337

SponsorNGM Biopharmaceuticals, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02

View on ClinicalTrials.gov More Mesothelioma trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of Patients with Dose-limiting Toxicities

Timeframe: Baseline up to 28 Days

Incidence of Adverse Events

Timeframe: Baseline up to Approximately 24 Months

Number of Patients with Clinically Significant Laboratory Abnormalities

Timeframe: Baseline up to Approximately 24 Months

Number of Patients in Expansion Cohorts with Objective Responses

Timeframe: Baseline up to approximately 24 months

Duration of Response for Patients in Expansion Cohorts

Timeframe: Baseline up to approximately 24 months

Progression-free Survival for Patients in Expansion Cohorts

Timeframe: Baseline up to approximately 24 months

Overall Survival for Patients in Combination Dose Expansion Cohorts

Timeframe: Up to approximately 48 months